Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts
David Lorente(Hospital Universitari i Politècnic La Fe), Johann S. de Bono(Royal Marsden NHS Foundation Trust), David Dolling(Institute of Cancer Research), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Penelope Flohr(Royal Marsden NHS Foundation Trust), Mateus Crespo(Institute of Cancer Research), Susana Miranda(Royal Marsden NHS Foundation Trust), David Olmos(Spanish National Cancer Research Centre), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Diletta Bianchini(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research), I. Figueiredo(Royal Marsden NHS Foundation Trust), Leon W.M.M. Terstappen(Düsseldorf University Hospital)
Cited by 97
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k